subscribeSubscribe
Aurinia: LUPKYNIS Profile In Lupus Nephritis At EULAR 2024

Aurinia: LUPKYNIS Profile In Lupus Nephritis At EULAR 2024
BUSINESSWIRE
05 Jun 2024
Share Share
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
BUSINESSWIRE
07 May 2024
Share Share
Aurinia brings singer Toni Braxton to Lupus Awareness Month push

Aurinia brings singer Toni Braxton to Lupus Awareness Month push
Nick Paul Taylor FIERCE PHARMA
01 May 2024
Share Share
FDA Approves Updated LUPKYNIS® Label With Long-Term AURORA Data

FDA Approves Updated LUPKYNIS® Label With Long-Term AURORA Data
BUSINESSWIRE
30 Apr 2024
Share Share
Otsuka Submits New Drug Application in Japan for Voclosporin

Otsuka Submits New Drug Application in Japan for Voclosporin
PRESS RELEASE
10 Nov 2023
Share Share
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
BUSINESSWIRE
19 Jul 2023
Share Share
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) a
BUSINESSWIRE
20 Jun 2023
Share Share
LUPKYNIS Achieved Higher Renal Response in Lupus Nephritis Patients

LUPKYNIS Achieved Higher Renal Response in Lupus Nephritis Patients
BUSINESSWIRE
01 Jun 2023
Share Share
Otsuka announces NICE recommendation of Lupkynis® (voclosporin)

Otsuka announces NICE recommendation of Lupkynis® (voclosporin)
BUSINESSWIRE
03 May 2023
Share Share
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®
BUSINESSWIRE
03 May 2023
Share Share